In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 201 to 250 of 408

TitleTypeExpected publication date
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidanceTBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Technology appraisal guidanceTBC
Managing common infections - antimicrobial prescribing guidelinesNICE guidelineTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]Technology appraisal guidanceTBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]Technology appraisal guidanceTBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liverInterventional procedures guidance
Mental health guidelinesNICE guidelineTBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237Technology appraisal guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NICE guideline
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]Technology appraisal guidanceTBC
Middle meningeal artery embolisation for chronic subdural haematomasInterventional procedures guidance
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]Technology appraisal guidance
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance
Monofocal intraocular lenses for cataract surgery (provisional title)Health technology evaluationTBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]Technology appraisal guidanceTBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremorInterventional procedures guidanceTBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]Technology appraisal guidanceTBC
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidanceTBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446Technology appraisal guidance
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]Technology appraisal guidanceTBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Technology appraisal guidanceTBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]Technology appraisal guidanceTBC
Nirogacestat for treating desmoid tumours [ID6453]Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Technology appraisal guidanceTBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Technology appraisal guidanceTBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]Technology appraisal guidanceTBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]Technology appraisal guidance
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidanceTBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Technology appraisal guidanceTBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All